Abzu is the best in class in silico disease understanding and drug design company. Since its founding in 2018, Abzu’s proprietary explainable AI, the QLattice®, has been the cornerstone to their cutting-edge approach. Abzu is a preferred partner for pharma, biotech, and research institutions, transforming data into insights and accelerating R&D.
Abzu has offices in Copenhagen and Barcelona, and has raised €13.3M in total funding to date. Abzu has been mentioned in Gartner® research, from Market Guides for AI Trust, Risk, and Security Management to Cool Vendor™, and is the winner of several awards, including the 2023 “Best HealthTech” Nordics Award at the Nordic Startup Awards.
-
Branche
-
Forskning inden for bioteknologi
-
Virksomhedsstørrelse
-
11-50 medarbejdere
-
Hovedkvarter
-
Nordhavn, Capital Region
-
Type
-
Privat
-
Grundlagt
-
2018
-
Specialer
-
RNA Therapeutics, RNA Tx, AI, artificial intelligence, explainable AI, trustworthy AI, QLattice, drug development, pharma og pharma R&D